Concepts (117)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Chromosomes, Human | 1 | 2014 | 130 | 0.440 |
Why?
|
| Chromosome Mapping | 2 | 2022 | 1096 | 0.410 |
Why?
|
| Cholesterol, HDL | 1 | 2014 | 398 | 0.400 |
Why?
|
| Coxsackie and Adenovirus Receptor-Like Membrane Protein | 1 | 2012 | 12 | 0.390 |
Why?
|
| Receptors, Thrombin | 1 | 2012 | 14 | 0.390 |
Why?
|
| Triglycerides | 1 | 2014 | 617 | 0.370 |
Why?
|
| Cholesterol, LDL | 1 | 2014 | 606 | 0.350 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2022 | 2850 | 0.330 |
Why?
|
| Blood Pressure | 1 | 2012 | 1402 | 0.260 |
Why?
|
| Sarcoma, Synovial | 1 | 2024 | 22 | 0.220 |
Why?
|
| Margins of Excision | 1 | 2024 | 57 | 0.220 |
Why?
|
| Breast Neoplasms | 6 | 2012 | 2675 | 0.210 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 1 | 2023 | 41 | 0.200 |
Why?
|
| Neonatal Screening | 1 | 2024 | 192 | 0.190 |
Why?
|
| Hepatoblastoma | 1 | 2023 | 183 | 0.170 |
Why?
|
| Congenital Abnormalities | 1 | 2024 | 299 | 0.170 |
Why?
|
| Obesity | 1 | 2012 | 2397 | 0.170 |
Why?
|
| Rhabdomyosarcoma | 1 | 2023 | 215 | 0.160 |
Why?
|
| Hepatitis C | 1 | 2022 | 387 | 0.140 |
Why?
|
| Behavior Rating Scale | 1 | 2016 | 6 | 0.120 |
Why?
|
| Executive Function | 1 | 2016 | 127 | 0.120 |
Why?
|
| Liver Cirrhosis | 1 | 2022 | 898 | 0.110 |
Why?
|
| Nutritional Status | 1 | 2016 | 294 | 0.110 |
Why?
|
| DNA Methylation | 2 | 2012 | 1120 | 0.110 |
Why?
|
| Child Behavior | 1 | 2016 | 236 | 0.110 |
Why?
|
| Receptors, Progesterone | 3 | 2012 | 681 | 0.100 |
Why?
|
| Child Development | 1 | 2016 | 271 | 0.100 |
Why?
|
| Liver Neoplasms | 1 | 2023 | 1381 | 0.100 |
Why?
|
| Prognosis | 6 | 2024 | 5013 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 2012 | 41 | 0.100 |
Why?
|
| LIM Domain Proteins | 1 | 2012 | 64 | 0.090 |
Why?
|
| ErbB Receptors | 2 | 2012 | 295 | 0.090 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2012 | 92 | 0.090 |
Why?
|
| Family | 1 | 2014 | 595 | 0.090 |
Why?
|
| Female | 14 | 2024 | 70691 | 0.090 |
Why?
|
| Cadherins | 1 | 2012 | 180 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 2 | 2012 | 1284 | 0.080 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2010 | 39 | 0.080 |
Why?
|
| Genome-Wide Association Study | 2 | 2023 | 1830 | 0.080 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2012 | 491 | 0.080 |
Why?
|
| Humans | 16 | 2024 | 132055 | 0.070 |
Why?
|
| Male | 8 | 2024 | 64944 | 0.070 |
Why?
|
| Carcinoma, Lobular | 1 | 2008 | 26 | 0.070 |
Why?
|
| Mastectomy | 1 | 2008 | 75 | 0.070 |
Why?
|
| Middle Aged | 8 | 2022 | 28979 | 0.070 |
Why?
|
| Mediator Complex | 2 | 2023 | 63 | 0.070 |
Why?
|
| Aged, 80 and over | 3 | 2014 | 7125 | 0.070 |
Why?
|
| Cytokines | 1 | 2012 | 1365 | 0.060 |
Why?
|
| Aged | 6 | 2014 | 21456 | 0.060 |
Why?
|
| India | 2 | 2016 | 238 | 0.060 |
Why?
|
| Patient Compliance | 1 | 2008 | 473 | 0.060 |
Why?
|
| Quality of Health Care | 1 | 2008 | 419 | 0.060 |
Why?
|
| Recurrence | 2 | 2023 | 1452 | 0.060 |
Why?
|
| Urban Population | 2 | 2016 | 245 | 0.060 |
Why?
|
| Anemia, Sickle Cell | 1 | 2008 | 330 | 0.060 |
Why?
|
| Receptors, Estrogen | 3 | 2012 | 740 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2012 | 1993 | 0.050 |
Why?
|
| Mass Screening | 1 | 2008 | 830 | 0.050 |
Why?
|
| Cardiovascular Diseases | 1 | 2014 | 2087 | 0.050 |
Why?
|
| Germ Cells | 1 | 2023 | 204 | 0.050 |
Why?
|
| Adult | 5 | 2014 | 31557 | 0.050 |
Why?
|
| Child, Preschool | 4 | 2024 | 14719 | 0.040 |
Why?
|
| Treatment Outcome | 5 | 2023 | 13015 | 0.040 |
Why?
|
| Reoperation | 1 | 2024 | 850 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2023 | 375 | 0.040 |
Why?
|
| Hepacivirus | 1 | 2022 | 272 | 0.040 |
Why?
|
| Stroke | 1 | 2008 | 1082 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2023 | 1460 | 0.040 |
Why?
|
| Receptor, ErbB-2 | 2 | 2012 | 549 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2024 | 17367 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2024 | 1304 | 0.030 |
Why?
|
| Cross-Sectional Studies | 2 | 2016 | 3753 | 0.030 |
Why?
|
| Registries | 1 | 2024 | 1591 | 0.030 |
Why?
|
| Neoplasm Staging | 2 | 2012 | 1364 | 0.030 |
Why?
|
| Body Weights and Measures | 1 | 2016 | 39 | 0.030 |
Why?
|
| Genotype | 1 | 2022 | 2703 | 0.030 |
Why?
|
| Texas | 1 | 2024 | 3632 | 0.030 |
Why?
|
| Child | 3 | 2024 | 25758 | 0.030 |
Why?
|
| Reference Values | 1 | 2016 | 703 | 0.030 |
Why?
|
| Linear Models | 1 | 2016 | 711 | 0.030 |
Why?
|
| Ploidies | 1 | 2012 | 38 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2012 | 396 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2024 | 8539 | 0.020 |
Why?
|
| Gene Order | 1 | 2011 | 82 | 0.020 |
Why?
|
| CpG Islands | 1 | 2012 | 342 | 0.020 |
Why?
|
| Developmental Disabilities | 1 | 2016 | 749 | 0.020 |
Why?
|
| Caspase 8 | 1 | 2010 | 25 | 0.020 |
Why?
|
| Frozen Sections | 1 | 2010 | 31 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2011 | 421 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2010 | 277 | 0.020 |
Why?
|
| Prevalence | 1 | 2016 | 2662 | 0.020 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2010 | 99 | 0.020 |
Why?
|
| Genes, Dominant | 1 | 2010 | 251 | 0.020 |
Why?
|
| Tamoxifen | 1 | 2011 | 354 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2010 | 295 | 0.020 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2011 | 265 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 1440 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2010 | 443 | 0.020 |
Why?
|
| Age of Onset | 1 | 2010 | 626 | 0.020 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2008 | 111 | 0.020 |
Why?
|
| Infant | 1 | 2023 | 13037 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2011 | 1571 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2010 | 770 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2010 | 1255 | 0.020 |
Why?
|
| Adolescent | 1 | 2024 | 20530 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2008 | 899 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2008 | 1126 | 0.010 |
Why?
|
| Age Factors | 1 | 2010 | 2921 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2011 | 2061 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 5407 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2008 | 1229 | 0.010 |
Why?
|
| Survival Rate | 1 | 2008 | 2192 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2008 | 898 | 0.010 |
Why?
|
| United States | 1 | 2016 | 11652 | 0.010 |
Why?
|
| Phenotype | 1 | 2010 | 4538 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2008 | 5168 | 0.010 |
Why?
|
| Young Adult | 1 | 2010 | 9938 | 0.010 |
Why?
|